Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
FUM is now 200million mcap
this is 10million mcap
WTF
Only £6000 left
Tightly held stock!!
this is female Viagra
female version of FUM
Good press coverage. Marked down on someone selling 40 shares. This has loads of potential here. Nothing else like it on the market.
thanks ... I'm happy to sit tight on this one then as (1) it builds to the application decision (2) more people notice it/ remember the assets it holds .
I doubt we will hear that much on the Auz / NZ trials as mgt are not the most talkative but a good update could push the sp up in the meantime
Either way happy to hold
Hi SlowLearner, sorry for delayed reply I had not visited the OVB board for a week or so as it has been very quiet. Noticed the SP tick up today and came for a look. Nice to see a few buys going thru, but not sure if it means anything.....
I can confirm that your understanding of the recent RNSs is in line with my understanding.
Pretty sure management will have taken care to have dotted every “I” and crossed every “T” in the resubmission because know their heads would have to roll if it got kicked back a second time....
So I believe this to be a potential multi bagger. Just need a little patience to let it play out..... :-)
Hi 28jaczar,
so i haven't been in OVB for a bit but looks like it's good value again .. people seem to regularly forget the assets its holds when the news flow is quiet (OVB's POLY shares up 7% today). Having said that can you confirm that I read the 5th January announcement right that the application was resubmitted for the Russian Market in January with decisions by September/October? Also it looks like investors have missed Friday's news the next wave of trials is starting in Australia (in preparation for an application to use in Western markets).
Feels like a bargain at under 10p
Stock being quietly accumulated with the SP ticking up nice and steady during this week. Seems to be smart long investors with patience getting on board now as they see the value here ahead of the game changing Russian approval expected later this year which should explode SP much higher.
Wow — Predicted that right ;)
Excellent to get confirmation of the resubmission......and also making progress outside of Russia.
Also nice to see the gold price has broken out yesterday and is quickly rising into the mid 1900s which increases the value of their POLY holding.
This stock looks a steal at under £10 million mcap.
nm
Added earlier and now they want the full 11p for small. Could easily move up 50 per cent on a few buyers
Let’s hope the new CBO can get things moving and the CMC sorted in super quick time ASAP. It might also be an idea for the company to put out some information about how things are moving along.
Thanks for the reply blaustein, you seem to have way more knowledge on this than I have and I hope everything you say comes true, a major delay of a year or so would not be good finance wise for obvious reasons. I did mention in a previous post that the finances OBV have are good and are strong enough to get them through to the result and further into the future, I still believe that to be the case even though it failed this time as the money and shares currently held is surely enough to get them through easily 1+ more years as they wont burn through over £10m that quick.
If, as you say, the delay I presumed being over a year possibly wont come to that then thats great for all holding and buying in. If/when OVB do get approval it will be a company maker for OBV, even if they sold if off it would be worth far more than the sp now. I do admit to not understanding what exactly it failed for this time and I was just basing my opinion on the timescale it took from last submission. Also as you mention OVB will update with more info in RNS's going forward to make the picture a bit more clearer what the schedule is from now on regarding re-submission.
I know I said I wouldn't reply again out of courtesy to holders but instead I'll change that to only reply if someone responds to me, I dont want to come across as a deramper as thats not what I am, I hope others can see that? Good luck in whatever happens, I realy mean that.
Spoon-key - thanks for responding to my initial post, & it is very helpful to read a differing view. None of us know really how things will now progress. I can only speak of my own impression, tempered with a very small experience of submitting applications to the DOH for research use of radiopharmaceuticals in humans in the UK.
Very few were successful at the first attempt, & I would have been surprised if OVB, as an ingenue pharma company, had received instant approval with no comeback. It seems perhaps that the delay was not due to bureaucratic inefficiency, as I had foolishly imagined - Minzhdrav seem to have done a proper professional job and the points they have raised will doubtless smooth the passage of submissions to the EU/US regulatory authorities in due course.
But I slightly doubt that OVB will now have to recommence the whole submission process. Minzhdrav will have been primarily concerned to ensure that the product is safe & efficacious, and therefore will have extensively reworked the data from the Phase I-III studies, to ensure that it met their quality standards, necessarily enlisting the help of external experts. It makes no sense to repeat this. Regulatory authorities often require clarification & reassurance, and many points can be dealt with quite quickly. Others of course can be more intractable. But, in the UK at least, one would have a fairly cordial but respectful dialogue with the individuals from the licensing authority at this point, so that the resubmission answered all of their concerns. Honour was then satisfied.
I don't know if things work similarly in Russia, but I would guess that they might.
I used to review papers submitted to a German medical journal, many of which came from eastern Europe. I was impressed by the Russians - their enthusiasm & scientific rigour, working with rather primitive research tools. Good people - great hosts and very open & direct, but their processes were very similar to our own.
So we will have to see, I guess. I would anticipate another RNS, when OVB can see their way more clearly. Their manufacturers do not seem to have completed their portion of the (voluminous ) application with adequate diligence. I wonder if they will change them?
Sorry but I disagree in regards to how long it will take. The RNS states "An update will be provided in due course on this review and Ovoca's plans for a full resubmission for MA in the Russian Federation." This to me says that it is atleast going to take the same amount of time if not longer than the year it took from sunmission to decision based on what they now have to do and how long it took for the decision to be made? This could now easily take the company into 2022 before drug decision after being re-submitted, this is not going to happen quickly please realise that.
After saying that the one thing people should now take note of is the sp is being held up by the money and shares in Poly OVO own which is a good thing BUT this is money now going to dwindle down quite a bit to cover costs over the period until the approval/denial comes again.
I just want to point out that I dont ramp/deramp shares but I do like to give people a view which may help but dont take anything I say as a reason to buy or sell its all just my opinion which to be honest mean nothing in the scheme of things! You should defo research what Ovo has and what could happen in the next year or so by reading over the RNS's. GL to all that decide to stay or decide to buy in, I wont post again to be fair to those that do hold.
Home straight.
It looks like the MA will be granted when these technical issues have been resolved. Might not take too long.
took How many years for the Ruskies to come up with those finding? Lol. Come back in 18 months
Personally bought on that drop. Certainly not a show stopped just a delay. Everything in Australia, EU and US is moving along as expected.
Minzhdrav are not questioning safety or efficacy - just "certain issues relating to the chemistry, manufacturing and controls (CMC) and labelling sections of the MA submission dossier". Fair enough - Russian authorities are doing their job, & the Company should have attended to these details beforehand. A set-back, but does it justify a 30% drop in SP, for a company whose value is under-written by its investment in POLY? A buying opportunity, IMHO.
Sounds like BP-101 is "good to go", just need a retest on a couple of advisories.
I'd say these are now cheap shares.
Some chunky buys going through today as folks take advantage to help themselves to the drop.